Cyclosporin A in combination with HAART in primary HIV-1 infection

Détails

ID Serval
serval:BIB_F4228C39B108
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Cyclosporin A in combination with HAART in primary HIV-1 infection
Périodique
Journal of Biological Regulators and Homeostatic Agents
Auteur(s)
Rizzardi  G. P., Vaccarezza  M., Capiluppi  B., Tambussi  G., Lazzarin  A., Pantaleo  G.
ISSN
0393-974X (Print)
Statut éditorial
Publié
Date de publication
03/2000
Volume
14
Numéro
1
Pages
79-81
Notes
Journal Article --- Old month value: Jan-Mar
Résumé
HAART is the cornerstone of HIV therapy, and has significantly reduced morbidity and mortality associated with HIV disease. The institution of HAART during the primary HIV-1 infection has a more profound influence on the ultimate pattern and rate of disease progression than therapy commenced later on. However, it also well demonstrated that HAART alone is not able to eradicate the virus, unless over a life-long period of time. There is therefore the need to develop alternative strategies aimed at modulating the immune responses in order to achieve the long-term control of HIV even once HAART is discontinued. Among immunomodulant agents, cyclosporin A in combination with HAART might play a role in the treatment of people with primary HIV-1 infection.
Mots-clé
Acquired Immunodeficiency Syndrome/*drug therapy Anti-HIV Agents/*administration & dosage CD4-CD8 Ratio Cyclosporine/*administration & dosage Drug Therapy, Combination *Hiv-1 Humans
Pubmed
Web of science
Création de la notice
25/01/2008 16:14
Dernière modification de la notice
03/03/2018 22:43
Données d'usage